|
|
|
|
|
||||||||||||
|
|
|
|
|
|
|
|
价值评估 |
盈利(现时/预测)
-2.20/-4.93
|
企业价值
4.87M
|
资产负债 |
每股账面净值
-0.36
|
现金流量 |
现金流量率
1.47
|
损益表 |
收益
12.05M
|
每股收益
3.96
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟:2024/05/17 23:55 EDT
同行比较之报价最少15分钟延迟
业务概览
|
|||
TRACON Pharmaceuticals Inc is a biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer and utilizing its cost efficient, contract research organization (CRO) independent productdevelopment platform to partner with ex-U.S. companies to develop and commercialize innovative products in the United States. The company's drug candidate includes Envafolimab, TRC102, TRC253, and Bispecific Antibodies. |